HORSHAM, Pa., Jan. 6 /PRNewswire/ -- Liquent, Inc. ("Liquent"), a leading provider of software and service solutions designed to support the regulatory business processes of life sciences companies, is pleased to announce that it has been acquired by Marlin Equity Partners ("Marlin") from Thomson Reuters. Based in Los Angeles, CA, Marlin is a leading private investment firm with over $1 billion of capital under management.
Liquent is the provider of Liquent InSight®, the industry's only fully integrated and scalable regulatory information management platform. InSight can be leveraged throughout a client organization in support of a life sciences company's development, registration, and manufacturing processes. Through its Regulatory and Clinical Services consulting services team, Liquent also provides a full range of outsourcing services to support the regulatory submission and registration management activities of a life sciences company. Liquent's current General Manager, Rick Riegel, will continue his leadership position as the CEO of the company.
"We are very excited to be partnering with such a strong private equity firm," commented Rick Riegel. "Marlin brings substantial financial resources and expertise in the healthcare IT sector. With their backing and Liquent's comprehensive software and service solutions, industry leadership, and focus on customer service, we look forward to accelerating our growth and ability to service the evolving and rapidly changing needs of the life sciences industry."
"Marlin recognizes the life sciences industry's constant struggle with regulatory change, new product approvals, and cost pressures. Marlin's backing combined with Liquent's software and outsourcing capabilities positions us well in helping our customers solve complex regulatory challenges," stated Jim Brady, Healthcare Operating Partner at Marlin Equity Partners.
About Marlin Equity Partners
Marlin Equity Partners is a Los Angeles, California-based private investment firm with over $1 billion of capital under management. The firm is focused on providing corporate parents, shareholders and other stakeholders with tailored solutions that meet their business and liquidity needs in special situations. Marlin invests in businesses across multiple industries that are in the process of undergoing varying degrees of operational, financial or market-driven change where its capital base, industry relationships and extensive network of operational resources significantly strengthens a company's outlook and enhances value. Since its inception, Marlin, through its group of funds and related companies, has successfully completed over 30 acquisitions. For more information, please visit www.marlinequity.com.
About Liquent, Inc.
Liquent regulatory solutions provide software and related regulatory and clinical services for the life sciences industry. These solutions and services help ensure clients meet the strict standards of regulatory authorities across the world helping them achieve quality, accuracy, and data integrity to deliver regulatory reports and submissions reliably and on time.
As a result, global life sciences companies, small tier to large tier, rely on Liquent regulatory solutions to provide the technology and services to compress the regulatory submissions and approval process, improving speed to market, cost control, and productivity, all of which contribute to ensuring patients' and physicians' timely access to new drugs. Over the last decade, thousands of regulatory submissions have been produced using Liquent world-class products and expert services. For more information please visit, www.liquent.com.
Contact: Rick Riegel Chief Executive Officer 215-328-4302
SOURCE Liquent, Inc.